All News

renal.genes_.jpg

Iberdomide in Systemic Lupus Erythematosus

d Jack Cush, MD

The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks. 

Read Article
Bronchiectasis_342x198_M1200048.jpg

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis

d Jack Cush, MD

Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.

Read Article
gout.toe_.MTP_.jpg

Disappointment Behind Acute Gout Hospitalizations

d Jack Cush, MD

Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management. 

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

d Jack Cush, MD

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Read Article
Baricitinib has been studied in 15 relapsing GCA pts - prospective, open-label, BARI 4 mg/d w/ GC taper. 14/15 completed 52 wks; 13/15 went into remission and d/c steroids. There was 1 Bari D/C for adverse event & 1 pt w/ serious AE. 1 pt relapsed. https://t.co/J5bjdPAFdm https://t.co/LsuSVP8L0R

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriasis RCT studied ADA+MTX (31) vs ADA (30); after 12 mos, a (non-significant) better drug survival w/ ADA-MTX (74 vs 59%; p=0.15). Also favoring, but not signif was PASI 75 (58 vs 37%). Fewer anti-ADA Abs seen w/ ADA-MTX (23 vs 60%; p<0.01) https://t.co/9CAQrpl6hU https://t.co/mr0ZaJ9mbW

Links:

Dr. John Cush RheumNow ( View Tweet)
Frailty: a decline in the physiologic reserve & function of several systems, leading to increased vulnerability and adverse health outcomes. Not just age; increased in RA (33%) more than AS or PsA. Frailty is dynamic & potentially reversible https://t.co/82hkGKoRxV https://t.co/7d9sycC6S2

Links:

Dr. John Cush RheumNow ( View Tweet)
Infants and children do get COVID; all races, 35% w/ comorbidities. CDC study from 99 counties in 14 US states shows betw 3/20 & 2/22 there were 2,637 hospitalized infants & children 0–4 yrs old; 24% went to ICU; there were 18 deaths https://t.co/mWyXAj2GbT https://t.co/MYN37JKziD

Links:

Dr. John Cush RheumNow ( View Tweet)

Abbvie announced that the FDA has approved Rinvoq (upadacitinib) for use in adults with active ulcerative colitis (after failing TNFi); approval based on 3 endoscopic UC trials. Starting dose is 45 mg/d, then maintain w/ 15 mg (some can get 30 mg) https://t.co/ZUbnkR7LMY https://t.co/dE1JkxzkSz

Links:

Dr. John Cush RheumNow ( View Tweet)
Another Rx for #PsA #psoriaticarthritis Deucravacitinib is shown to be effective. Good news but this adds to the dilemma of what to use in PsA Rx and in what order. Rational Rx may need #personalized Rx for best bang for buck! https://t.co/JQs7BlQwos

Links:

Janet Pope Janetbirdope ( View Tweet)

Individualized Therapy in Ankylosing Spondylitis Whether patients with AS would improve substantially with TNF inhibitor therapy was predicted with moderate to high accuracy based on a lab test and two measures of disease activity, researchers reported. https://t.co/hbbYqTiWGE https://t.co/Hx2U4y2e0F

Links:

Dr. John Cush RheumNow ( View Tweet)
Intravenous (IV) form of tramadol (Schedule IV) went in front of the FDA Drug Safety & Risk and Anesthetic/Analgesic Advisory Committees yesterday. They voted 14-8 against approval of IV tramadol (now available as tabs, liquid) https://t.co/AP2G7w8z1h https://t.co/lr9aLJSKi6

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Efficacy in Rheumatoid Arthritis A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA). https://t.co/ycDgLT9EAA https://t.co/NJi48FZzAa

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis looked at the risk of psoriasis or PsA flare associated with steroid use. 11 retro- and prospective cohorts (4,170 820 pts) w/ 38% of PsA & 35% psoriasis Rx w/ systemic steroids. 10/11 studies did not show increased flares w/ steroids https://t.co/8o8hINFOrr https://t.co/85OYtWnGMJ

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available on Methotrexate overview. https://t.co/dpyS4TS6tf https://t.co/2VsiqdX7WU

Links:

Dr. John Cush RheumNow ( View Tweet)
Who's to Blame? A Patient with Psoriatic Arthritis Dies from Sepsis - what was the cause of sepsis and death? QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/lUfQHpNIOc https://t.co/HHk4hFs5ZS

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against GM-CSF is capable of inducing clinical remission. https://t.co/QmACP1ESFG https://t.co/EeWxTZuFbw

Links:

Dr. John Cush RheumNow ( View Tweet)
Doctors in the Dark The modern way to real-time consult with specialists QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/rd5blbrORD https://t.co/O5X64tKNmh

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Spondylitis in At-Risk Relatives The risk of developing axSpA if you’re a first-degree relative (FDRs) of an AS patient has been defined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of AAU. https://t.co/wezFZUhyZZ https://t.co/VASbJZt9UV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us on Saturday either in-person or virtually! https://t.co/GY4ZPderis https://t.co/OIo5QHBqEF

Links:

Dr. John Cush RheumNow ( View Tweet)

×